A clinical formulation indicated for Asthma and Breathing and COVID-19. Promotes improved respiratory function by reducing fibrotic activity within the lung tissue.
Indicated to mitigate lung scarring progression by addressing abnormal cell signaling to support improved respiratory function in patients with chronic fibrosing lung diseases.
Mechanism of Action
Nintedanib blocks several receptors that are responsible for the growth of scar tissue in the lungs. By inhibiting these signals, it slows the thickening and stiffening of lung tissue, helping to preserve breathing capacity.
Route of Administration
Oral
Onset Time
Variable; months for clinical change
Duration
12 hours
Contraindications
Severe liver impairment, Hypersensitivity to nintedanib, Pregnancy
Severe Adverse Events
Severe liver injury, Gastrointestinal perforation, Heart attack, Severe bleeding, Severe hypertension
Information for Nintedanib is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
